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Resection and replacement of the inferior vena
cava (IVC) for removal of malignant disease has
been performed rarely because of the magnitude and
risk of the operation.1-10 Often, patients with can-
cers invading or obstructing the vena cava have dis-
tant metastases at the time of the diagnosis or they
are too ill for an operation to be considered. Because
effective treatment alternatives are few, resection
remains the only hope for cure or palliation of their
symptoms. Partial resection of the caval wall, with
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Objectives: Resection and replacement of the inferior vena cava (IVC) to remove malig-
nant disease is a formidable procedure. Since our initial report with IVC replacement for
malignancy, we have maintained an aggressive approach to these patients. The purpose
of this review is to update our experience with regard to patient selection, operative tech-
nique, and early and late outcome.
Methods: All patients who had IVC replacement for primary (n = 2) or secondary (n =
27) vena cava tumors from April 1990 to May 1999 were reviewed. Tumor location and
type, clinical presentation, the segment of IVC replaced, graft patency, performance sta-
tus of the patient, and tumor recurrence and survival data were collected. Late follow-
up data were available for all but one patient. The IVC was replaced in 28 patients with
large diameter (≥14 mm) externally supported ePTFE grafts and with a panel graft of
superficial femoral vein in the other. Three patients had a femoral arteriovenous fistula.
Graft patency was determined before hospital dismissal and in follow-up by vena cavog-
raphy, computed tomography, ultrasonography, or magnetic resonance imaging.
Results: There were 18 women and 11 men, with a mean age of 53.1 years (range, 16-
88 years). Over one half of patients had symptoms from their tumor. IVC replacement
was at the suprarenal segment in 15 patients, of whom 13 had concomitant major
hepatic resection, at the infrarenal segment in 10, at both caval segments in three, and
at the renal vein confluence in one. There were two early deaths (6.9%). One patient
died intraoperatively of coagulopathy during liver resection and suprarenal IVC
replacement. The other death occurred 4 months postoperatively, from multisystem
organ failure that resulted in graft infection and occlusion. Twelve patients had one or
more major complications— cardiopulmonary problems in five; bleeding in five; chy-
lous ascites or large pleural effusions in two patients each; and lower extremity edema
with tibial vein thrombosis in one. The mean follow-up was 2.8 years (range, 2.7
months to 6.3 years). Two late graft occlusions occurred: one at 7.5 months, the other,
from tumor recurrence, at 6.3 years. There have been no other late graft-related com-
plications. All 11 late deaths were caused by the progression of malignant disease. Of
16 survivors, 12 have no evidence of disease and four have either regional or distant
metastatic recurrence. Initial postoperative performance status was good or excellent
for most survivors.
Conclusions: Aggressive surgical management may offer the only chance for cure or pal-
liation of symptoms for patients with primary or secondary IVC tumors. Our experience
suggests that vena cava replacement may be performed safely with low graft-related mor-
bidity and good patency in carefully selected patients. (J Vasc Surg 2000;31:270-81.)
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either primary or patch closure, is preferable to graft
replacement because it is safer and easier to per-
form.3,10 Additionally, resection of the infrarenal
segment of the IVC may be preferable to graft
replacement for patients with chronic vena cava
obstruction and established venous collaterals.11
Earlier in this decade, we recognized a few good-
risk patients with localized cancers or sarcomas for
whom tumor clearance and chance for cure was pos-
sible only with resection or replacement of the vena
cava. At that time, we began an aggressive treatment
approach for these patients, one that included en
bloc tumor resection and vena cava replacement at
all levels, including replacement of the retrohepatic
vena cava in conjunction with major liver resection.1
Here, we report an updated experience with empha-
sis on patient selection, technical factors, and early
and late outcome.
METHODS
The cases for all patients who had graft replace-
ment of the IVC between April 1990 and May 1999
were reviewed. Patients who had excision of a por-
tion of the IVC with primary or patch closure, those
who had transcaval removal of tumor thrombus
related to renal cell carcinoma or other tumors, and
those with IVC ligation or resection alone were
excluded from analysis.
The patient’s clinical presentation, the type and
location of the tumor, the segment of vena cava
replaced, graft patency, performance status of the
patient preoperatively and postoperatively, and
tumor recurrence and survival were collected for all
patients by review of their clinic records, by tele-
phone interview, or by letter. Late follow-up data
were available for all but one patient.
A multidisciplinary approach was used in the eval-
uation and treatment of these patients. Initially, all
patients were seen in the Division of Medical
Oncology at the Mayo Clinic. Chest roentgenogra-
phy, computed tomography (CT), ultrasonography,
or magnetic resonance imaging (MRI) were used to
exclude the presence of metastatic disease, to assess
local resectability of the tumor, and to assess the
extent of involvement and obstruction of the IVC
(Fig 1). Early in our experience, vena cavography was
used preoperatively to determine the degree of caval
obstruction and the presence of venous collaterals,
and to help plan the operation. At present, vena
cavography is used only if the venous anatomy is not
shown well by the other imaging studies. If the
tumor was found locally resectable, an extensive
medical evaluation of the patient was performed to
assess operative risk. The patient’s performance status
was determined by using criteria outlined by Zubrod
et al,12 which provides an assessment of the patient’s
physical conditioning and has been a useful measure
Fig 1. A, CT scan of patient with a large leiomyosarcoma
involving the right lobe of the liver, right kidney, and
retroperitoneum (white arrows). The retrohepatic seg-
ment of the suprarenal inferior vena cava was invaded by
the tumor (black arrow). The patient underwent tumor
and liver resection with IVC replacement. B, CT scan of
patient with a retroperitoneal leiomyosarcoma surround-
ing the infrarenal IVC. The tumor is shown by the large
black arrow. This patient also required resection of the
infrarenal aorta, shown by the smaller black arrow. (Fig
1,A from Bower TC. Primary and secondary tumors of
the inferior vena cava. In: Handbook of venous disorders:
guidelines of the American Venous Forum. Gloviczki P,
Yao JST, editors, pages 529-550; Fig 1,B from Bower TC,
Stanson AW. Evaluation and management of malignant
tumors of the inferior vena cava. In: Rutherford R, editor.
Vascular surgery, 5th ed. Orlando, Fla: WB Saunders, in
press. Used by permission.)
A
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Fig 2. Key steps in performance of retrohepatic IVC
replacement and liver resection. A, Early isolation of the
suprahepatic and infrahepatic IVC. B, Vascular isolation of
the liver just prior to completion of tumor and IVC resec-
tion. C, Upper caval anastomosis performed with vascular
isolation of the liver. Some patients require venovenous
bypass to maintain stable hemodynamics. 
A B
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of functional quality of life for patients with malig-
nant disease. A scoring system from 0 to 4 is used. A
score of 0 indicates the patient is fully active, a score
of 4 indicates that the patient is bedridden, and
scores from 1 through 3 indicate varying degrees of
physical limitation between these extremes. No
options for curative treatment other than resection
were considered available for these patients.
By definition, the infrarenal segment of the IVC
extended from the confluence of the common iliac
veins to the origin of the renal veins. The suprarenal
segment extended from the renal veins to the hepatic
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veins, and the suprahepatic segment was between the
hepatic veins and the right atrium. Tumors were clas-
sified as primary only if pathologic review and the
operative findings clearly determined the origin of the
tumor from the vein wall. All other tumors were clas-
sified as secondary tumors. All but one patient had
replacement of the IVC with externally supported
polytetrafluoroethylene grafts (ePTFE; 14-20 mm in
diameter). The other patient had replacement of the
infrarenal and suprarenal IVC with a panel graft of
superficial femoral vein. Heparin was given intra-
venously during the time of caval replacement, but the
dose varied according to the type of operation, the
amount of blood loss, and the discretion of the sur-
geon. The heparin dose ranged from 0 up to 5000
units. All patients received antibiotics perioperatively.
In the patients who had suprarenal cava replace-
ment with concomitant liver resection, the proximal
caval anastomosis either incorporated the left hepatic
vein or was extended to the level of the remaining
hepatic vein. Our operative technique in these cases
has been described previously.1,10 The key aspects of
the operation include the following: a right thoracoab-
dominal incision in the seventh, eighth or ninth inter-
costal space; thorough intra-abdominal exploration to
exclude regional lymph node or peritoneal metastatic
disease; intraoperative ultrasonography to determine
the presence of tumor nodules and their proximity to
the major vascular structures; isolation of the supradi-
aphragmatic extra-pericardial vena cava as a fixed point
for application of the cross-clamp; early ligation of the
hepatic artery and portal vein branches to the segment
to be resected; avoidance of dissection of the hepatic
vein of the liver remnant; total hepatic vascular isola-
tion of the liver to complete the liver resection and to
perform the upper caval anastomosis; the selected use
of venovenous bypass with use of a magnetically cou-
pled mechanical pump (Bio-Medicus Pump, Model
#520D; Bio-Medicus, Eden Prairie, Minn) to maintain
the patient’s systolic blood pressure above 100
mmHg; and reattachment of the ligaments of the
hepatic remnant to avoid torsion of the hepatic venous
outflow (Fig 2). In all cases, the graft was wrapped
with omentum or other retroperitoneal tissue.
Fig 2 Cont’d. D, Blood flow is re-established through the liver, and the lower caval anasto-
mosis is completed. E, Completed graft reconstruction with reattachment of the ligaments of
the liver to avoid torsion of the hepatic venous outflow. (Fig 2,A,C,D from Bower TC, Stanson
AW. Evaluation and management of malignant tumors of the inferior vena cava. In: Rutherford
R, editor. Vascular surgery, 5th ed. Orlando, Fla: WB Saunders; in press; and Fig 2,B from
Bower TC, Nagorney DM, Toomey BJ, et al. Vena cava replacement for malignant disease: Is
there a role? Ann Surg 7:51-62. Used by permission.)
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Postoperatively, all patients had pneumatic com-
pression devices applied to the lower extremities and
started receiving subcutaneous heparin or low-dose
intravenous heparin within 24 to 48 hours. Warfarin
(Coumadin) therapy was begun after resumption of
nutrition per os. The dose was adjusted to maintain
the international normalized ratio between 2.0 and
3.0, and the patients kept receiving warfarin indefi-
nitely. Patients with retrohepatic IVC replacement
and liver resection had ischemic injury to the liver
monitored with serum assays for aspartate transami-
nase, alkaline phosphatase, total bilirubin, and pro-
thrombin time. Graft patency was documented in the
early postoperative period and during follow-up by
one or more studies including vena cavography, con-
trast-enhanced CT scan, ultrasonography, or MRI.
The last imaging study that confirmed patency of the
graft was used as the end point to calculate graft
patency. These same imaging studies were used to
determine the presence of recurrent or metastatic dis-
ease. Adjuvant radiation or chemotherapy was given
to selected patients depending on the tumor type.
RESULTS
Twenty-nine patients had IVC replacement for
removal of primary (n = 2) or secondary (n = 27)
tumors. By comparison, more than 9800 operations
were performed for abdominal cancers at our insti-
tution during this same period and more than 250
patients had operations for renal cell carcinoma with
tumor thrombus in the past 20 years. The 29
patients of this study represent 21.8% of the 133
graft reconstructions of the iliac veins or the superi-
or or inferior vena cava performed at our institution
for benign or malignant disease.
There were 18 women and 11 men, with a mean
age of 53.1 years (range, 16-88 years). The suprarenal
IVC was replaced in 15 patients, of whom 13 had
major concomitant hepatic resection and replacement
of the retrohepatic IVC segment. Ten patients had
replacement of the infrarenal IVC, three had both
segments replaced with reimplantation of the left
renal vein onto the graft, and the last patient had
reconstruction of the IVC at the renal vein conflu-
ence. The details of eight of these patients have previ-
ously been reported.1
Over two thirds of the patients were initially seen
with one or more symptoms from their tumor,
including pain in 17 (58.6%), weight loss, fatigue, or
nausea in seven (24.1%), and lower extremity edema
in three (10.3%). Only one patient presented with
lower extremity deep vein thrombosis. Nine patients
(31.0%) were asymptomatic but had a mass discov-
ered either by physical examination or incidentally
with an imaging study.
Twelve patients had previous operations for
tumor resection (n = 9) or for exploration and biop-
sy (n = 3). Ten patients received preoperative adju-
vant therapy in the form of chemotherapy (n = 2),
radiation therapy (n = 5), or both (n = 3). Ten
patients had intraoperative radiation therapy, and 11
received adjuvant therapy postoperatively.
Infrarenal vena cava replacement. Ten patients
had replacement of the infrarenal IVC through a
midline or subcostal abdominal incision. All of the
tumors in this group were secondary malignancies.
Eight tumors (80%) were sarcomas, with leiomyosar-
coma being most common. Other details regarding
this group are shown in Table I. An arteriovenous fis-
tula was created between the superficial femoral
Table I. Operative data and early and late outcome of 10 patients with infrarenal IVC replacement
Age/Sex Tumor type Concomitant procedure Graft size (mm) Intraop blood (units)
60/M Liposarcoma R nephrectomy; IORT 16 9
43/M Adeno Ca R nephrectomy; IORT 16 1
20/M Germ cell Duodenal resection 20 0
74/F Leiomyosarcoma None 14 7
88/F Leiomyosarcoma AV fistula 16 2
60/M Leiomyosarcoma Replacement infrarenal aorta; IORT 20 5
58/F Leiomyosarcoma R nephrectomy; IORT 16 5
47/M Leiomyosarcoma R nephrectomy; IORT 20 0
16/F Liposarcoma Appendectomy 20 0
43/F Malignant fibrous histiocytoma R nephrectomy; AV fistula; IORT 16 8
R, Right; IORT, intraoperative radiation treatment; NED, no evidence of disease; Ca, carcinoma; AV, arteriovenous.
*Documented by imaging studies.
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artery and the saphenous vein in two patients. These
fistulas were closed at 3.5 months and 6.1 months
after operation.
Suprarenal vena cava replacement. Thirteen of
15 patients with suprarenal IVC replacement had con-
comitant major liver resection and replacement of the
retrohepatic vena cava for primary liver cancers (n = 7),
leiomyosarcoma (n = 3), or metastatic colon cancer to
the liver (n = 3) (Table II). This group represents less
than 1% of all patients who have had liver resection for
cancer at our institution during this same period. No
adjunctive femoral arteriovenous fistulas were placed
in these patients. The extent of liver resection and the
other organs removed are shown in Table II.
The other two patients had suprarenal but infra-
hepatic IVC replacement for locally recurrent
leiomyosarcoma or liposarcoma. One of these patients
required left renal vein reimplantation, and one had a
femoral arteriovenous fistula created (Table II).
Suprarenal and infrarenal IVC replacement
Three patients had both the infrarenal and
suprarenal segments of the IVC replaced (Table III).
All of them had reconstruction or reimplantation of
the left renal vein onto the graft. None of these
patients had an arteriovenous fistula.
Another patient had reconstruction of the IVC
at the renal vein confluence in addition to an ePTFE
patch placed from the graft onto the left renal vein
to prevent stenosis.
Mortality and morbidity. Two deaths occurred,
for an overall perioperative mortality rate of 6.9%. One
patient died intraoperatively of coagulopathy during
attempted resection of a large central liver tumor and
the retrohepatic IVC. The other in-hospital death
occurred 4 months postoperatively, from multisystem
organ failure resulting from a duodenal perforation.
This patient had a small area of graft contamination
found at reoperation for the duodenal leak even
though the graft had been covered by omentum. An
initial attempt was made to salvage the graft, but a sub-
sequent operation for abdominal sepsis showed the
graft was occluded, infected, and needed to be
removed. Sixteen patients (55.2%) recovered without
complication. Major morbidity included cardiopul-
monary problems in five patients, of which one was a
hemodynamically significant anterior wall myocardial
infarction; bleeding in five patients, of whom two
required reoperation and one required percutaneous
drainage of a hematoma; chylous ascites or large pleur-
al effusions in two patients each; and bile leak, bilater-
al lower extremity edema with tibial vein thrombosis,
and wound infection in one patient each (Tables
I–III). The patient with the autologous caval graft had
a bile leak and a hematoma, both of which required
percutaneous drainage to control. The biloma and
hematoma caused significant extrinsic compression of
the upper end of the caval graft. The graft stenosis was
treated with a 16-mm self-expanding stent.
Graft patency. There were three graft occlu-
sions (Fig 3). One graft occluded in the patient who
died in the hospital 4 months after operation.
Another graft occluded 7.5 months postoperatively
in a patient who had replacement of both caval seg-
ments and reconstruction of the left renal vein. With
the exception of a serum creatinine level of 1.7
mg/dL, this patient has had no sequelae from the
graft occlusion. One suprarenal caval graft occluded
6.3 years postoperatively in a patient in whom recur-
rent liver cancer caused hepatic venous outflow
Late Outcome
Complications Graft patency* (years) Status (years) Tumor recurrence
None Patent (1.9) Alive (2.1) NED
Reexploration for bleeding Patent (1.1) Alive (1.1) NED
Respiratory distress–mucous plug Patent (2.6) Alive (4.0) NED
None Patent (6.0) Dead (6.2) Regional, distant
Congestive heart failure; atrial fibrillation Patent (0.3) Alive (4.7) NED
None Patent (3.0) Alive (3.3) NED
None Patent (2.1) Alive (2.1) NED
Bleeding, ascites Patent (0.0) Alive (0.5) NED
Ascites Patent (3.0) Alive (3.0) NED
Bleeding Patent (4.4) Dead (4.4) Regional
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obstruction. There were no other late graft-related
complications (Tables I–III).
Postoperative liver function. Serum markers of
liver function peaked within 3 days of operation and
returned to normal levels before hospital dismissal in
patients with suprarenal IVC replacement who had
concomitant liver resection. Alkaline phosphatase
levels peaked toward the end of hospitalization. No
patient had liver failure develop after retrohepatic
IVC replacement and concomitant liver resection.
Survival and tumor recurrence. Mean follow-up
was 2.8 years, and the median follow-up was 2.9 years
(range, 2.7 months to 6.3 years). Despite the variety of
malignancies, overall survival was calculated by using
Kaplan-Meier survival estimates with 95% confidence
intervals. One-year survival was 89.3% (78.5% to
100%); 2-year survival was 80.3% (66.1% to 97.6%);
and 3-year survival was 75.0% (59.1% to 95.0%). Just
beyond 3 years, the Greenwood standard error of the
mean exceeded 10%. The mean survival was 3.14 years
in the group with infrarenal IVC replacement, 2.88
years in the group who had both IVC segments
replaced, and 2.26 years in the group with suprarenal
caval replacement. If the two in-hospital deaths are
excluded, mean survival in the latter group was 2.58
years. Our longest survivor lived 6.33 years.
There were 11 late deaths from regional or dis-
tant metastatic disease. Of 16 survivors, 12 have no
Table II. Operative data and early and late outcome of 15 patients with suprarenal IVC replacement
Age/sex Tumor type Extent of liver resection* Concomitant procedure Intraop blood (units)
53/F Adeno Ca IV-A, V-VIII None 57
66/M Adeno Ca I, V-VIII Cholecystectomy 4
47/M Adeno Ca I, V-VIII Cholecystectomy, Wedge resection R pulmonary nodule 2
55/M Cholangio Ca I, V-VIII Cholecystectomy 10
71/M Cholangio Ca I, IV-A, V-VIII None 9
43/F Leiomyosarcoma I Adrenalectomy 5
24/M Leiomyosarcoma IV, VI-VII R nephrectomy, Cholecystectomy, Adrenalectomy 5
39/F Leiomyosarcoma IV R nephrectomy 3
64/F Hepatocellular I, V-VIII Cholecystectomy, Wedge excision R lower lobe of lung 4
70/F Hepatocellular IV-A, VII-VIII Cholecystectomy 29
52/F Cholangio Ca III, IV-A Cholecystectomy 5
65/F Cholangio Ca I-IV Cholecystectomy; splenectomy 16
65/F Cholangio Ca VII R nephrectomy; adrenalectomy 6
53/F Liposarcoma None IORT 3
43/F Leiomyosarcoma None AV fistula; IORT 2
Ca, Carcinoma; R, right; NED, no evidence of disease; AV, arteriovenous; IORT, intraoperative radiation treatment.
*Segments of liver resected according to Couinand C, ed. Surgical anatomy of the liver revisited. Paris: Couinand, 1989.
†Documented by imaging studies.
‡No documented patency prior to death.
Table III. Operative data and early and late outcome of four patients with replacement of the infrarenal 
and suprarenal IVC
Age/sex Tumor type IVC portion reconstructed Concomitant procedure Graft size (mm)
66/F Leiomyosarcoma Both segements IORT SFV panel graft (16)
22/F Leiomyosarcoma Both segements R nephrectomy, 20
Adrenalectomy
60/F Primary leiomyosarcoma Both segements R nephrectomy, Adrenalectomy, 16
IORT
72/M Primary leiomyosarcoma IVC at renal vein confluence None 20†
IORT, Intraoperative radiation treatment; SFV, superficial femoral vein; NED, no evidence of disease; R, right.
*Documented by imaging studies.
†Reconstruction of the IVC with a 20-mm ePTFE cut graft and ePTFE patch of left renal vein.
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evidence of disease and 4 either have regional or dis-
tant metastatic recurrence (Tables I–III). The initial
postoperative performance status of the 27 survivors
was good (performance status = 1) or excellent (per-
formance status = 0) in 26 (96.3%). One patient was
bedridden over half the time and capable of limited
self-care (performance status = 3).
DISCUSSION
The role of IVC resection and replacement for
the treatment of malignant disease is limited to a
small number of select patients. Only 29 patients
have had graft replacement of the IVC for malig-
nancy at our institution during a period in which
almost ten thousand operations have been per-
formed for abdominal cancers or sarcomas. This
group represents less than 10% of patients who have
had operations for malignant disease involving the
vena cava—the most common being renal cell carci-
noma with tumor thrombus. Ultimately, the goal of
these operations is to cure the patient of malignancy
or to provide prolonged palliation of symptoms.
However, data regarding the survival of patients
with primary or secondary caval malignancies is
sparse. The largest collection of information to
address this issue is from an international registry of
218 patients with primary leiomyosarcomas of the
IVC compiled by Mingoli et al.13 With radical
Late outcome
Complications Graft patency* (years) Status (years) Tumor recurrence
Intraop death — Dead (0.0) —
None Patent (0.9) Dead (3.2) Distant
None Unknown‡ Dead (1.1) Regional
None Patent (0.8) Dead (1.3) Regional; distant
Myocardial infarction Patent (2.6) Dead (3.1) Distant
None Patent (2.6) Dead (3.7) Regional; distant
None Patent (2.5) Dead (2.7) Regional; distant
None Patent (4.4) Alive (4.4) Regional, distant
None Patent (0.2) Dead (0.8) Regional; distant
Pleural effusions; lower extremity edema; Occluded (6.3) Dead (6.3) Regional
tibial vein thrombosis
None Patent (1.1) Alive (1.1) NED
Atrial fibrillation Patent (0.5) Alive (1.0) Regional; distant
None Patent (0.8) Alive (0.9) NED
Death (4 mo)–duodenal leak Occluded at 18 days; infected Dead (0.3) —
None Patent (1.9) Dead (4.0) Distant
Late outcome
Intraop blood (units) Complications Graft patency* (years) Status (years) Tumor recurrence
6 Hematoma, Bile leak, Graft stenosis Patent (0.2) Alive (0.2) NED
15 Pleural effusion, Superficial Patent (2.6) Alive (2.6) Regional
wound infection
5 None Occluded (0.6) Alive (2.9) NED
2 None Patent (5.8) Alive (5.8) Regional, Distant
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tumor resection, 5- and 10-year survival rates were
49.4% and 29.5%, respectively, whereas mean sur-
vival was only 3 months for untreated patients.13,14
For the types of tumors resected in this series, medi-
an survival would be estimated to be 1 year or less.
Our 3-year survival was 75% and was better in the
groups of patients who had infrarenal IVC replace-
ment and those with replacement of both caval seg-
ments. The prevalent tumor type in these two
groups were sarcomas. The mean survival in patients
with suprarenal caval replacement, often done in
conjunction with major liver resection for primary or
metastatic liver cancers, was lower than the other
two groups of patients. The survival in this group is
still higher than would be expected if the patients’
tumors were not resected. Although there is a trend
toward improvement in survival in these patients,
the diverse etiology of cancers herein and the small
number of patients preclude conclusions regarding
the impact of these operations on survival.
The role of vena cava reconstruction for the
treatment of malignant disease is in its early evolu-
tion, and only a few surgeons have focused on its
development.1-3 Moreover, although irradiation or
chemotherapy alone has no proven benefits for these
types of tumors, we believe a multi-modal approach
has theoretic benefit. If radical tumor resection and
caval replacement are to have any role, the operative
mortality and morbidity must be low, patients must
be carefully selected, and the grafts must be durable.
The operative mortality in our patients is low,
given the magnitude of the procedure, and is consis-
tent with other reports.2,3 One of six patients with
suprarenal IVC resection by Huguet et al2 died of
acute renal failure, and two of 18 patients operated
on by Kieffer et al3 for primary and secondary IVC
tumors died postoperatively. Major morbidity with
vena cava resection or replacement includes hepatic
failure, cardiopulmonary problems, postoperative
ascites, renal insufficiency, lower extremity edema,
or graft occlusion or infection. Whether the IVC
should be replaced after resection for malignant dis-
ease is unresolved. We agree with others that resec-
tion of the infrarenal segment of the vena cava with-
out reconstruction is appropriate for those patients
in whom the vena cava is occluded or extensively
scarred from tumor or from prior adjuvant therapy,
for those in whom there are well-developed venous
collaterals demonstrated by preoperative studies,
and for those in whom concomitant intestinal resec-
tion is required.11
Beck et al11 reviewed the long-term venous
sequelae of 24 patients on whom data was available
out of 65 who were operated on for retroperitoneal,
nonseminomatous germ cell tumors that included
infrarenal vena cava resection only. Postoperative
acute renal failure occurred in four patients, lower
extremity edema in four, and chylous ascites in
three. These authors were unable to predict late
venous sequelae on the basis of preoperative venous
symptoms, signs, or imaging. They postulated that
long-term venous sequelae occurred rarely because
vena cava occlusion occurred slowly as the cancer
enlarged. However, if vena cava occlusion occurs
more quickly, postoperative edema may occur in
36% to 70% of patients and late edema or venous
problems may affect over one third.15,16
Some authors have suggested that the suprarenal
IVC may also be safely resected and not replaced.
However, the ability to predict which patients will tol-
erate resection of the vena cava at this level without
subsequent renal insufficiency or lower extremity
edema is difficult.2,17 The former complication is more
apt to occur in patients who have had, or will require,
right nephrectomy and in whom the left renal vein
may need to be ligated at operation to resect the
tumor.2,10 A transient rise in the serum creatinine level
or permanent renal insufficiency may occur in as many
as one half of patients who require left renal vein liga-
tion in these situations.2,18 In a recent report, of six
patients who had resection of the suprarenal IVC with
or without replacement, one with a chronic caval
occlusion preoperatively tolerated IVC resection with-
out sequelae, whereas another with more rapid evi-
dence of caval obstruction had renal failure develop. A
third patient required reimplantation of the left renal
Fig 3. Survival without graft occlusion by Kaplan-Meier
estimates. The data points were determined on the basis of
the last imaging study that confirmed patency of the caval
graft.
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vein onto a caval graft to reverse intraoperative anuria.2
Based on this experience, those authors believe that
renal vein reconstruction should be performed at this
level if the patient has anuria or a marked decrease in
urine output during the period of renal vein cross-
clamping.2 This principle applies whether the right or
left renal vein requires reimplantation.
In contrast, we favor caval replacement at all levels
in those patients in whom the IVC is not obstructed
but requires resection for tumor clearance, in those
without well-developed venous collaterals, in those
whose collateral veins had to be ligated or resected for
tumor removal, and in those who require replacement
of the IVC at or above the level of the renal vein con-
fluence. With this approach, only four (14%) of our
patients developed pleural effusions or chylous ascites,
which were controlled by percutaneous drainage, and
only one had lower extremity edema. With the excep-
tion of the patient who died of multisystem organ fail-
ure while in the hospital, no other patient had acute
renal failure or graft infection develop.
Careful patient selection is critical to outcome.
We believe that a multidisciplinary approach to the
evaluation and treatment of these patients is an inte-
gral component for patient selection. Most patients
are imaged with CT scan to define the extent of the
tumor and the presence of metastatic disease. In our
early experience, vena cavography was performed
preoperatively to define the venous anatomy. We no
longer routinely use this study but reserve it for
patients with suspected IVC occlusion or those with
signs or symptoms of venous or renal insufficiency
for whom the IVC is not adequately imaged by CT
scan or MRI. Most patients we see with cancers
involving the IVC have advanced disease, are debili-
tated, or have metastases—all of which exclude them
from consideration of operation. We do offer surgi-
cal treatment to patients with localized cancers and
caval involvement only if they have no significant
renal, liver, or cardiopulmonary dysfunction and
their performance status is near normal.
A number of operative principles are important
to minimize the mortality and morbidity in these
cases. First, careful review of the location of the
tumor in relation to major vascular structures is crit-
ical, especially if concomitant major liver resection is
anticipated. Our only intraoperative death was of a
patient with a large central liver tumor that abutted
all three major hepatic veins. Attempt at resection
resulted in uncontrolled bleeding and death from
coagulopathy. In retrospect, our attempt should
have been aborted because of the anatomic proxim-
ity of the tumor to all of the hepatic veins. Second,
the choice of incision for resection of the tumor and
IVC replacement is important. Abdominal midline
or bilateral subcostal incisions are used to replace the
infrarenal and infrahepatic segment of the vena cava,
but we prefer a right thoracoabdominal incision for
exposure of the retrohepatic vena cava in patients for
whom a right or extended right hepatectomy is con-
templated. This latter incision allows for mobiliza-
tion of the liver and isolation of the supradiaphrag-
matic vena cava, and it provides excellent exposure
of the suprarenal vena cava. Intraoperative ultra-
sonography has been a valuable adjunct in these sit-
uations to clarify the intrahepatic extent of tumor
and to confirm hepatic venous outflow and portal
vein and hepatic artery inflow to the anticipated
hepatic remnant. Once resectability is confirmed,
blood loss during the hepatic resection is minimized
by early ligation of the appropriate afferent and
efferent lobar vasculature before parenchymal divi-
sion. The use of hepatic vascular exclusion allows for
completion of the tumor resection and performance
of the upper caval anastomosis in what is essentially
a bloodless field. Liver ischemia was less than 30
minutes in most of our patients and under 1 hour in
all but one patient—well within the tolerable limits
of ischemia reported for the liver by others.19
Finally, the selected use of venovenous bypass to
shunt blood from the infrarenal IVC into the central
venous system has been helpful to maintain hemo-
dynamics during the period of suprahepatic IVC
cross-clamp time.
The durability of caval grafts after operation
appears good. We, and others, have preferred the use
of externally supported ePTFE grafts for replacement
of the IVC for both benign and malignant condi-
tions.1-10,20,21 These grafts are widely available, can be
sized matched to the diameter of the vena cava, and
have the theoretic advantage of being resistant to com-
pression by overlying abdominal viscera.1,3 Because
ePTFE grafts tend to form a thick pseudointima, we
prefer the use of grafts larger than 16 mm in diameter
and a length as short as possible.22 Our graft occlusion
rate was 10.7%, and one occlusion was related to
recurrent tumor. There were no graft occlusions
among the three survivors with suprarenal IVC
replacement reported by Huguet et al2 or of the four
IVC grafts placed for treatment of primary and sec-
ondary caval malignancies by Kieffer and associates.3
Dartevelle et al21 have had a similar graft occlusion rate
with the use of ePTFE grafts for venous reconstruction
of the innominate veins or superior vena cava for medi-
astinal or pulmonary tumors. None of our patients
with graft occlusion had an arteriovenous fistula con-
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structed at the initial operation. In fact, only three of
our patients had an arteriovenous fistula. Despite our
graft patency rate and limited use of a fistula, our data
are insufficient to define the role of an arteriovenous
fistula in this clinical setting. We agree with others that
an arteriovenous fistula is not required if the suprarenal
or suprahepatic vena cava is reconstructed because of
the large blood flow volume at this level.2 However,
our experience with iliocaval or femorocaval recon-
structions for treatment of benign disease suggests that
an arteriovenous fistula may enhance graft patency 
for long grafts (ie, ones used to replace more than 
one caval segment) or small-diameter grafts (≤16
mm).20,22
In addition to the low graft occlusion rate, the
risk of infection of synthetic caval grafts in the
abdomen appears to be low. One of our deaths was
of a patient in whom multisystem organ failure from
a duodenal leak caused a secondary infection of the
graft. However, we have not yet encountered any
other late clinical graft infections, even though two
have had resection of a portion of the duodenum,
one had a bile leak, and another had a wound infec-
tion develop. Similarly, Huguet et al2 reported no
late graft infection after suprarenal caval resection.
Nonetheless, we have performed one autologous
IVC reconstruction because of concern about the
possibility of a duodenal leak.
The last issue to be considered is the effect of
an operation on the patient’s quality of life. We
arbitrarily chose the use of a performance status
scale to help us predict the tolerance of these
patients to surgery. This assessment has been used
at our institution for other patients undergoing
cancer resection and is a useful analysis in assessing
risk of and outcome after an operation. In our ini-
tial experience with vena cava replacement for
malignant disease, 82% of the patients maintained
their fitness level postoperatively. This trend has
continued and likely reflects the strict criteria for
patient selection.
In summary, we believe that aggressive surgical
management may offer the only chance for cure or
palliation of symptoms in select patients with pri-
mary or secondary tumors of the IVC. Patients with
localized disease, no significant medical problems,
and a good preoperative performance status should
be considered candidates for tumor resection. Our
experience suggests that vena cava replacement 
can be performed safely with few graft-related com-
plications.
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